ArTS Archivio della ricerca di Trieste

ROCCA, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.029
NA - Nord America 2.712
EU - Europa 1.356
SA - Sud America 533
AF - Africa 75
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 1
Totale 7.711
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.593
SG - Singapore 1.071
CN - Cina 628
IT - Italia 531
BR - Brasile 402
HK - Hong Kong 359
VN - Vietnam 290
KR - Corea 238
BD - Bangladesh 145
DE - Germania 114
FR - Francia 110
NL - Olanda 92
IN - India 87
SE - Svezia 81
RU - Federazione Russa 70
CH - Svizzera 69
GB - Regno Unito 68
CA - Canada 57
PL - Polonia 57
FI - Finlandia 42
AR - Argentina 41
MX - Messico 32
TW - Taiwan 32
IE - Irlanda 25
ID - Indonesia 24
EC - Ecuador 22
MA - Marocco 22
AT - Austria 20
CO - Colombia 20
TR - Turchia 19
IQ - Iraq 18
CL - Cile 16
AE - Emirati Arabi Uniti 14
PH - Filippine 14
JP - Giappone 13
UA - Ucraina 13
PK - Pakistan 12
PY - Paraguay 12
ES - Italia 11
SA - Arabia Saudita 11
TH - Thailandia 9
UZ - Uzbekistan 9
VE - Venezuela 9
EG - Egitto 8
IR - Iran 8
KE - Kenya 8
RO - Romania 8
SN - Senegal 8
BE - Belgio 7
TT - Trinidad e Tobago 7
UY - Uruguay 7
ZA - Sudafrica 7
BG - Bulgaria 6
DZ - Algeria 6
JM - Giamaica 6
LT - Lituania 5
CR - Costa Rica 4
CZ - Repubblica Ceca 4
XK - ???statistics.table.value.countryCode.XK??? 4
AL - Albania 3
AZ - Azerbaigian 3
BO - Bolivia 3
GE - Georgia 3
GR - Grecia 3
GT - Guatemala 3
HU - Ungheria 3
IL - Israele 3
JO - Giordania 3
MY - Malesia 3
NO - Norvegia 3
PT - Portogallo 3
SI - Slovenia 3
TN - Tunisia 3
BS - Bahamas 2
CI - Costa d'Avorio 2
ET - Etiopia 2
NI - Nicaragua 2
NP - Nepal 2
PA - Panama 2
QA - Qatar 2
RS - Serbia 2
SV - El Salvador 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
AU - Australia 1
BF - Burkina Faso 1
BH - Bahrain 1
CM - Camerun 1
DK - Danimarca 1
DM - Dominica 1
GA - Gabon 1
HN - Honduras 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LY - Libia 1
MR - Mauritania 1
Totale 7.703
Salva come PNG Salva come JPEG
Città #
Singapore 595
Ashburn 461
Hong Kong 354
San Jose 323
Hefei 247
Seoul 234
Boardman 158
Beijing 152
Council Bluffs 139
Dallas 106
Ho Chi Minh City 99
Santa Clara 99
Trieste 87
Milan 77
Los Angeles 67
Chicago 61
New York 60
Bern 59
Hanoi 58
Lauterbourg 54
Columbus 48
São Paulo 46
Zgierz 38
Buffalo 36
The Dalles 33
Princeton 32
Moscow 31
Rome 29
Frankfurt am Main 28
London 28
Taipei 27
Memphis 26
Dublin 24
Seattle 24
Houston 23
Helsinki 22
North Bergen 22
Pune 21
Nuremberg 20
Atlanta 17
Orem 17
Redondo Beach 17
Toronto 16
Düsseldorf 15
Fairfield 15
Lappeenranta 15
Miano 15
Munich 15
Rio de Janeiro 15
Boydton 14
Denver 14
Amsterdam 13
Montreal 13
Shanghai 13
Chennai 12
Warsaw 12
Quito 11
Stockholm 11
Tappahannock 11
Brasília 10
Casablanca 10
Chandler 10
Treviso 10
Dhaka 9
Haiphong 9
Hangzhou 9
Naples 9
Phoenix 9
Vienna 9
Wilmington 9
Woodbridge 9
Ankara 8
Dakar 8
San Donà di Piave 8
Santiago 8
Tashkent 8
Bologna 7
Brussels 7
Da Nang 7
Jacksonville 7
Jakarta 7
Philadelphia 7
San Francisco 7
Apodaca 6
Asunción 6
Biên Hòa 6
Brooklyn 6
Can Tho 6
Duino-Aurisina 6
Itaquaquecetuba 6
Kingston 6
Shenzhen 6
Tokyo 6
Torviscosa 6
Washington 6
Ann Arbor 5
Belo Horizonte 5
Cambridge 5
Cleveland 5
Dubai 5
Totale 4.627
Salva come PNG Salva come JPEG
Nome #
Complement protein C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma 199
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial 193
Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report 190
A tailored machine learning approach for mortality prediction in severe COVID-19 treated with glucocorticoids 184
179 C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma 181
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT 174
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer 159
Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients 154
The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets 146
Ribociclib and Endocrine Therapy in Breast Cancer 125
Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer 112
Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis 110
CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study 109
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 108
Can Systems Biology Advance Clinical Precision Oncology? 107
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab 103
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 103
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer 100
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study 98
A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer 96
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? 96
Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer 94
Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study 93
Androgen receptor signaling pathways as a target for breast cancer treatment 92
Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial 91
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? 91
A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy 91
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer 90
Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ 90
Identifying the best treatment choice for relapsing/refractory glioblastoma: a systematic review with multiple Bayesian network meta-analyses 89
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemo-immunotherapy in patients with advanced melanoma 87
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer? 86
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial 86
Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer 84
Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy 84
Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression 84
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 83
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial 83
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter 83
A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer 82
Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype 82
A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer 81
Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience 81
[Prophylaxis of toxic effects on the peripheral venous system associated with intravenous administration of vinorelbine] 81
Precision medicine: PI3K targeting in advanced breast cancer 80
A phase II study of primary dose-dense sequential doxorubicin plus cyclophosphamide and docetaxel in cT4 breast cancer 79
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 79
Early C-reactive protein reduction predicts survival in COVID-19 severe pneumonia treated with glucocorticoids 78
HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer 77
Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas 77
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 76
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report 76
WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis 76
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels 73
Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population? 72
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer 72
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer. A case report 71
Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial 71
Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy 69
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer 68
Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer 68
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer 65
Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients 64
Investigating biochemical markers of Acupuncture's effectiveness in managing climacteric syndrome in breast cancer patients: the FLAIR study 57
The dynamics of tumour-vasculature interaction suggests low-dose, time-dense anti-angiogenic schedulings 51
Hyperfractionated radiotherapy in locally advanced nasopharyngeal cancer. An analysis of 43 consecutive patients 50
Multicentric/multifocal breast cancer with a single histotype: is the biological characterization of all individual foci justified? 49
Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies 47
CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience 45
Oxaliplatin combined with 5-fluorouracil and methotrexate in advanced colorectal cancer 45
Existence and relevance of fulminant severe community-acquired pneumonia 44
Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneity 44
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel 39
Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients 38
Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence 37
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer 36
Virtual Biomarkers and Simplified Metrics in the Modeling of Breast Cancer Neoadjuvant Therapy: A Proof-of-Concept Case Study Based on Diagnostic Imaging 35
Circulating tumor cells in early breast cancer: A connection with vascular invasion 35
Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course 34
Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer 32
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer 31
Radiotherapy, morphine, and bone pain: a difficult relationship? 31
Reliability of Left Ventricular Ejection Fraction from Three-Dimensional Echocardiography for Cardiotoxicity Onset Detection in Patients with Breast Cancer 31
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer 31
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer 30
Diagnosis and management of neck metastases from an unknown primary 30
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects 30
Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy 30
CTCs in early breast cancer: A path worth taking 29
Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: the Milan Cancer Institute experience 27
Circulating endothelial cell number and viability are reduced by exposure to high altitude 27
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer 27
Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy 26
Update: current management issues in malignant melanoma 26
Paraneoplastic hypocalcemia-induced heart failure in advanced breast cancer: A case report and literature review 26
Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients 26
Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy 26
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines  for the adjuvant treatment of early breast cancer? 25
Breast cancer vaccines: a clinical reality or fairy tale? 23
Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents 23
Totale 7.499
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.465
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.465
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202251 1 0 0 0 0 1 0 2 1 14 3 29
2022/2023470 16 2 9 19 32 65 2 100 101 8 95 21
2023/2024701 89 43 32 63 63 54 92 112 20 35 65 33
2024/20251.950 19 167 308 104 157 114 226 88 265 172 121 209
2025/20264.582 401 483 317 304 259 273 493 120 506 682 393 351
2026/2027110 110 0 0 0 0 0 0 0 0 0 0 0
Totale 7.942